Pharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting review by the FDA, according to a new report from US trade body PhRMA
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
